REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Replimune Group, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$11.05+0.19 (+1.75%)
Close on Oct 19, 2026
- Market cap
- $1.07B
- P/E (TTM)
- –
- Dividend yield
- –
Community
Notes and questions about Replimune from other investors
No posts about REPL yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.